Citations

Mayo Clinic

Showing 10 of 108551 citations.

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction
Landau, Heather , Comenzo, Raymond L. , Seldin, David C. , Weiss, Brendan M. , Zonder, Jeffrey A. , Merlini, Giampaolo , Schönland, Stefan , Walling, Jackie , Kinney, Gene G. , Koller, Martin, Schenk, Dale B., Guthrie, Spencer , Liedtke, Michaela , Seldin, David, Weiss, Brendan, Zonder, Jeffrey, Guthrie, Spencer D, Gertz, Morie A. , Merlini, Giampaolo , Schönland, Stefan

Journal of Clinical Oncology | February 8, 2016 | Volume: 34 | Issue: 10 | Pages: 1097-1103

10.1200/jco.2015.63.6530 | PMID 26858336 Get It

Purpose Light chain (AL) amyloidosis is caused by the accumulation of misfolded proteins, which induces the dysfunction of vital organs. NEOD001 is a monoclonal antibody targeting these misfolded proteins. We report interim data from a phase I/II dose-escalation/expansion study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction (NCT01707264). Patients and Methods Patients who had completed at least one previous anti–plasma cell-directed therapy, had partial hematologic response or better, and had persistent organ dysfunction received NEOD001 intravenously every 28 days. Dose levels of 0.5, 1, 2, 4, 8, 16, and 24 mg/kg were evaluated (3 + 3 study design). Primary objectives were to determine the maximum tolerated dose and the recommended dose for future studies and to evaluate safety/tolerability. Secondary and exploratory objectives included pharmacokinetics, immunogenicity, and organ responses on the basis of published consensus criteria. Results Twenty-seven patients were enrolled in seven cohorts (dose-escalation component). No drug-related serious adverse events (AEs), discontinuations because of drug-related AEs, dose-limiting toxicities, or antidrug antibodies were reported. The most frequent AEs were fatigue, upper respiratory tract infection, cough, and dyspnea. Recommended dosing was 24 mg/kg. Pharmacokinetics support intravenous dosing every 28 days. Of 14 cardiac-evaluable patients, eight (57%) met the criteria for cardiac response and six (43%) had stable disease. Of 15 renal-evaluable patients, nine (60%) met the criteria for renal response and six (40%) had stable disease. Conclusion Monthly infusions of NEOD001 were safe and well tolerated. Recommended future dosing was 24 mg/kg. Organ response rates compared favorably with those reported previously for chemotherapy. A phase II expansion is ongoing. A global phase III study (NCT02312206) has been initiated. Antibody therapy targeting misfolded proteins is a potential new therapy for the management of AL amyloidosis.
Juvenile idiopathic arthritis and future risk for cardiovascular disease: a multicenter study
Anderson, JH, Anderson, KR, Aulie, HA, Crowson, CS , Mason, T. G., Ardoin, SP, Reed, AM, Flatø, Berit , Anderson, Jason H. , Aulie, Hanne Aaserud , Ardoin, Stacy P. , Anderson, Jason

Scandinavian Journal of Rheumatology | February 8, 2016 | Volume: 45 | Issue: 4 | Pages: 299-303

10.3109/03009742.2015.1126345 | PMID 26854592 Get It

Prevention of Surgical Site Infections in Joint Replacement Surgery
Marculescu, Camelia, Mabry, Tad M. , Berbari, Elie F. , Mabry, Tad

Surgical Infections | February 8, 2016 | Volume: 17 | Issue: 2 | Pages: 152-157

10.1089/sur.2015.258 | PMID 26855288 Get It

Understanding inherited genetic risk of adult glioma – a review
Rice, Terri, Molinaro, Annette M. , Eckel‐Passow, Jeanette E. , Walsh, Kyle M. , Barnholtz‐Sloan, Jill S. , Francis, Stephen , Wiemels, Joseph L. , Jenkins, Robert B. , Wrensch, Margaret , Barnholtz-Sloan, Jill, Francis, Stephen S, Wiemels, Joseph, Wiencke, John K. , Wrensch, Margaret R, Lachance, Daniel Honore , Molinaro, Annette M. , Ostrom, Quinn T. , Barnholtz-Sloan, Jill S , Francis, Stephen S

Neuro-Oncology Practice | February 8, 2016 | Volume: 3 | Issue: 1 | Pages: 10-16

10.1093/nop/npv026 | PMID 26941959 Get It

Abstract During the past six years, researchers have made major progress identifying common inherited genetic variation that increases risk for primary adult glioma. This paper summarizes knowledge about rare familial cancer syndromes that include adult glioma and reviews the available literature on the more recently discovered common inherited variation. Ten independent inherited variants in eight chromosomal regions have been convincingly associated with increased risk for adult glioma. Most of these variants increase relative risk of primary adult glioma by 20% to 40%, but the TP53 variant rs78378222 confers a two-fold relative risk (ie, 200%), and rs557505857 on chromosome 8 confers a six-fold relative risk of IDH-mutated astrocytomas and oligodendroglial tumors (ie, 600%). Even with a six-fold relative risk, the overall risk of developing adult glioma is too low for screening for the high-risk variant on chromosome 8. Future studies will help clarify which inherited adult glioma risk variants are associated with subtypes defined by histology and/or acquired tumor mutations. This review also provides an information sheet for primary adult glioma patients and their families.
Friendly Fire-The Bane of Thermal Ablation
Padmanabhan, Deepak , Asirvatham, Samuel J. , Asirvatham, Samuel J

Pacing and Clinical Electrophysiology | February 8, 2016 | Volume: 39 | Issue: 4 | Pages: 313-315

10.1111/pace.12825 | PMID 26854190 Get It

Novel Percutaneous Epicardial Autonomic Modulation in the Canine for Atrial Fibrillation: Results of an Efficacy and Safety Study
Madhavan, Malini , Venkatachalam, K, Swale, M., Gard, Joseph J., Johnson, Susan B., Suddendorf, Scott H., Mikell, Susan B. , Ladewig, Dorothy J., NOSBUSH, TONI GRABINGER, Danielsen, Andrew J., Knudson, Mark B., Asirvatham, Samuel J. , Knudson, Mark, DeSimone, Christopher V. , Asirvatham, Samuel J

Pacing and Clinical Electrophysiology | February 8, 2016 | Volume: 39 | Issue: 5 | Pages: 407-417

10.1111/pace.12824 | PMID 26854009 Get It

BackgroundEndocardial ablation of atrial ganglionated plexi (GP) has been described for treatment of atrial fibrillation (AF). Our objective in this study was to develop percutaneous epicardial GP ablation in a canine model using novel energy sources and catheters.MethodsPhase 1: The efficacy of several modalities to ablate the GP was tested in an open chest canine model (n = 10). Phase 2: Percutaneous epicardial ablation of GP was done in six dogs using the most efficacious modality identified in phase 1 using two novel catheters.ResultsPhase 1: Direct current (DC) in varying doses (blocking [7–12 μA], electroporation [300–500 μA], ablation [3,000–7,500 μA]), radiofrequency ablation (25–50 W), ultrasound (1.5 MHz), and alcohol (2–5 mL) injection were successful at 0/8, 4/12, 5/7, 3/8, 1/5, and 5/7 GP sites. DC (500–5,000 μA) along with alcohol irrigation was tested in phase 2. Phase 2: Percutaneous epicardial ablation of the right atrium, oblique sinus, vein of Marshall, and transverse sinus GP was successful in 5/6 dogs. One dog died of ventricular fibrillation during DC ablation at 5,000 μA. Programmed stimulation induced AF in six dogs, preablation and no atrial arrhythmia in three, flutter in one, and AF in one postablation. Heart rate, blood pressure, effective atrial refractory period, and local atrial electrogram amplitude did not change significantly postablation. Microscopic examination showed elimination of GP, and minimal injury to atrial myocardium.ConclusionPercutaneous epicardial ablation of GP using DC and novel catheters is safe and feasible and may be used as an adjunct to pulmonary vein isolation in the treatment of AF in order to minimize additional atrial myocardial ablation.
FusX: A Rapid One-Step Transcription Activator-Like Effector Assembly System for Genome Science
Alvin, C. H. , McNulty, Melissa S. , Poshusta, Tanya L., Campbell, Jarryd M. , Martínez‐Gálvez, Gabriel , Argue, David P., Lee, Han , Urban, Mark D. , Bullard, Cassandra E., Blackburn, Patrick R. , Man, Toni Ki Fong, Clark, Karl J. , Ekker, Stephen C. , Ma, Alvin C, Lee, Han B, Ekker, Stephen C , Lee, Han B , Clark, Karl J

Human Gene Therapy | February 8, 2016 | Volume: 27 | Issue: 6 | Pages: 451-463

10.1089/hum.2015.172 | PMID 26854857 Get It

Transcription activator-like effectors (TALEs) are extremely effective, single-molecule DNA-targeting molecular cursors used for locus-specific genome science applications, including high-precision molecular medicine and other genome engineering applications. TALEs are used in genome engineering for locus-specific DNA editing and imaging, as artificial transcriptional activators and repressors, and for targeted epigenetic modification. TALEs as nucleases (TALENs) are effective editing tools and offer high binding specificity and fewer sequence constraints toward the targeted genome than other custom nuclease systems. One bottleneck of broader TALE use is reagent accessibility. For example, one commonly deployed method uses a multitube, 5-day assembly protocol. Here we describe FusX, a streamlined Golden Gate TALE assembly system that (1) is backward compatible with popular TALE backbones, (2) is functionalized as a single-tube 3-day TALE assembly process, (3) requires only commonly used basic molecular biology reagents, and (4) is cost-effective. More than 100 TALEN pairs have been successfully assembled using FusX, and 27 pairs were quantitatively tested in zebrafish, with each showing high somatic and germline activity. Furthermore, this assembly system is flexible and is compatible with standard molecular biology laboratory tools, but can be scaled with automated laboratory support. To demonstrate, we use a highly accessible and commercially available liquid-handling robot to rapidly and accurately assemble TALEs using the FusX TALE toolkit. Together, the FusX system accelerates TALE-based genomic science applications from basic science screening work for functional genomics testing and molecular medicine applications.
Extended ellipse-line-ellipse trajectory for long-object cone-beam imaging with a mounted C-arm system
Yu, Zhicong , Lauritsch, Günter, Dennerlein, Frank, Mao, Yanfei , Hornegger, Joachim, Noo, Frédéric , Mao, Yanfei

Physics in Medicine & Biology | February 8, 2016 | Volume: 61 | Issue: 4 | Pages: 1829-1851

10.1088/0031-9155/61/4/1829 | PMID 26854687 Get It

Abstract Recent reports show that three-dimensional cone-beam (CB) imaging with a floor-mounted (or ceiling-mounted) C-arm system has become a valuable tool in interventional radiology. Currently, a circular short scan is used for data acquisition, which inevitably yields CB artifacts and a short coverage in the direction of the patient table. To overcome these two limitations, a more sophisticated data acquisition geometry is needed. This geometry should be complete in terms of Tuy’s condition and should allow continuous scanning, while being compatible with the mechanical constraints of mounted C-arm systems. Additionally, the geometry should allow accurate image reconstruction from truncated data. One way to ensure such a feature is to adopt a trajectory that provides full R-line coverage within the field-of-view (FOV). An R-line is any segment of line that connects two points on a source trajectory, and the R-line coverage is the set of points that belong to an R-line. In this work, we propose a novel geometry called the extended ellipse-line-ellipse (ELE) for long-object imaging with a mounted C-arm system. This trajectory is built from modules consisting of two elliptical arcs connected by a line. We demonstrate that the extended ELE can be configured in many ways so that full R-line coverage is guaranteed. Both tight and relaxed parametric settings are presented. All results are supported by extensive mathematical proofs provided in appendices. Our findings make the extended ELE trajectory attractive for axially-extended FOV imaging in interventional radiology.
Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know?
Gershman, Boris , Boorjian, Stephen A. , Hautmann, Richard E.

Bladder Cancer | February 8, 2016 | Volume: 2 | Issue: 1 | Pages: 1-14

10.3233/blc-150022 | PMID 27376120 Get It

T1 bladder cancer constitutes approximately 25% of incident bladder cancers, and as such carries an important public health impact. Notably, it has a heterogeneous natural history, with large variation in reported oncologic outcomes. Optimal risk-stratification is essential to individualize patient management, targeting those at greatest risk of progression for aggressive therapies such as early cystectomy, while allowing others to safely pursue bladder-preserving approaches including intravesical bacillus Calmette-Guerrin (BCG). Current strategies for diagnosis, risk-stratification, and treatment are imperfect, but emerging technologies and molecular approaches represent exciting opportunities to advance clinical paradigms in management of this disease entity.
Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report
Jawad, Majd, Begna, Kebede H. , Reichard, Kaaren K. , Jawad, Majd D, Go, Ronald S. , Ketterling, Rhett P. , Shi, Min

Clinical Case Reports | February 8, 2016 | Volume: 4 | Issue: 3 | Pages: 282-286

10.1002/ccr3.506 | PMID 27014453 Get It

Key Clinical MessageTyrosine kinase inhibitor treated chronic myelogenous leukemia patients with monosomy 7 arising in Philadelphia chromosome negative (Ph−) cells tend to evolve into MDS/AML. However, monosomy 7 in Ph− cells can be a transient finding, and it is not an absolute indication of the emergence of a new myeloid malignancy.